Overview of the most common skin adverse reactions of biological treatment in patients with inflammatory bowel disease – part 1

Czech version

Authors: M. Nováková ^1,2
Authors‘ workplace: Dermatovenerologická klinika 2. LF UK a FN Bulovka, Praha 2 Dermatovenerologická ambulance, IKEM, Praha ¹
Published in: Gastroent Hepatol 2023; 77(1): 70-76
Category:

Sources

1. Lambert JLW, De Schepper S, Speeckaert R. Cutaneous Manifestations in Biological-Treated Inflammatory Bowel Disease Patients: A Narrative Review. J Clin Med 2021; 10 (5): 1040. doi: 10.3390/jcm10051040.

2. Ungureanu L, Cosgarea R, Alexandru Badea M et al. Cutaneous manifestations in inflammatory bowel disease (Review). Exp Ther Med 2020; 20 (1): 31–37. doi: 10.3892/etm.2019.8321.

3. Antonelli E, Bassotti G, Tramontana M et al. Dermatological Manifestations in Inflammatory Bowel Diseases. J Clin Med 2021; 10 (2): 364. doi: 10.3390/jcm10020364.

4. Pasadyn SR, Knabel D, Fernandez AP et al. Cutaneous adverse effects of biologic medications. Cleve Clin J Med 2020; 87 (5): 288–299. doi: 10.3949/ccjm.87a.19119.

5. Lee J, Lemons N, Lorenze A et al. Management of cutaneous side effects of inflammatory bowel disease therapy: A dermatologic viewpoint. J Gastroenterol Hepatol 2021; 36 (12): 3278–3285. doi: 10.1111/jgh.15570.

6. Xie W, Xiao S, Huang H et al. Incidence of and Risk Factors for Paradoxical Psoriasis or Psoriasiform Lesions in Inflammatory Bowel Disease Patients Receiving Anti-TNF Therapy: Systematic Review With Meta-Analysis. Front Immunol 2022; 13: 847160. doi: 10.3389/fimmu.2022.847 160.

7. Jeong KM, Seo JY, Kim A et al. Tumor Necrosis Factor-Alpha Inhibitor-Associated Psoriatic Alopecia in a Patient with Ulcerative Colitis: A Case Report and Review of the Literature. Ann Dermatol 2021; 33 (1): 82–85. doi: 10.5021/ad.2021.33.1.82.

8. Revankar R, Patel H, Rojas M et al. Systematic review of TNFa-induced paradoxical psoriasis: Treatment outcomes of switching to alternative biologic therapies in inflammatory bowel disease patients. J Dermatolog Treat 2022: 1–4. doi: 10.1080/09546634.2022.2133533.

9. Giagkou E, Saridi M, Albani E et al. Dermal Lesions and Skin Cancer in Patients with Inflammatory Bowel Disease Receiving Immunosuppressive Therapy. Asian Pac J Cancer Prev 2018; 19 (10): 2845–2851. doi: 10.22034/APJCP.2018.19.10.2845.

10. Macaluso FS, Sapienza C, Ventimiglia M et al. Lupus-like reactions in patients with inflammatory bowel disease treated with anti-TNFs are insidious adverse events: data from a large single-center cohort. Scand J Gastroenterol 2019; 54 (9): 1102–1106. doi: 10.1080/00365521.2019.1663260.

11. Picardo S, So K, Venugopal K. Anti-TNF-induced lupus in patients with inflammatory bowel disease. JGH Open 2019; 4 (3): 507–510. doi: 10.1002/jgh3.12291.

12. McPhie ML, Wang A, Molin S et al. Lichen planopilaris induced by infliximab: A case report. SAGE Open Med Case Rep 2020; 8: 2050313X20901967. doi: 10.1177/205031 3X20 901967.

13. Garcovich S, De Simone C, Genovese G et al. Paradoxical Skin Reactions to Biologics in Patients With Rheumatologic Disorders. Front Pharmacol 2019; 10: 282. doi: 10.3389/fphar.2019.00 282.

14. Miedema J, Nunes H. Drug-induced sarcoidosis-like reactions. Curr Opin Pulm Med 2021; 27 (5): 439–447. doi: 10.1097/MCP.0000000000000800.

15. Hertl M. Severe Cutaneous Adverse Drug Reactions. In: Plewig G, French L, Ruzicka T et al (eds). Braun-Falco’s Dermatology. Berlin, Heidelberg: Springer 2022. Dostupné z: https: //doi.org/10.1007/978-3-662-63709-8_36.

16. Toledo-Martinez JF, Galdamez-Carcamo EV, Somoza-Cano FJ et al. Recurrent Steven-Johnson/Toxic Epidermal Necrolysis Overlap Syndrome. Cureus 2022; 14 (1): e21364. doi: 10.7759/cureus.21364.

17. Qudsiya Z, Waseem M. Dermatomyositis. 2022. In: StatPearls [online]. Treasure Island (FL): StatPearls Publishing 2022.

18. Keller R, Mazurak N, Fantasia L et al. Quality of life in inflammatory bowel diseases: it is not all about the bowel. Intest Res 2021; 19 (1): 45–52. doi: 10.5217/ir.2019.00135.